Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

(2013)   LANCET NEUROLOGY

The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

(2013) James D. Berry et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis

(2012) Brian C. Healy et al.   MUSCLE & NERVE

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics

(2012) Stacy A. Rudnicki et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Modeling drop-outs in amyotrophic lateral sclerosis

(2011) Paolo Messina et al.   Contemporary Clinical Trials

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

(2010) Linda Wittkop et al.   Clinical Trials

Effects of gender in amyotrophic lateral sclerosis

(2010) Pamela A. McCombe et al.   Gender Medicine

Progression in ALS is not linear but is curvilinear

(2010) Paul H. Gordon et al.   JOURNAL OF NEUROLOGY

Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study

(2007) S Zoccolella et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY